FDA's use of guidance documents will be focus of Sept. 14 House hearing.
This article was originally published in The Tan Sheet
Executive Summary
FDA's USE OF GUIDANCE DOCUMENTS WILL BE FOCUS OF SEPT. 14 CONGRESSIONAL HEARING to be held by two subcommittees of the House Government Reform Committee: Rep. Christopher Shays' (R-Conn.) Human Resources Subcommittee and Rep. David McIntosh's (R-Ind.) Regulatory Affairs Subcommittee. The hearing, which will focus on FDA enforcement issues, will examine the extent to which FDA requires compliance with guidance documents that are not promulgated as regulations.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning